A value investing screen combining Zacks Rank #1 (Strong Buy) stocks with low P/S ratios (under 1.0) and PEG ratios (under 1.0) identified 12 stocks offering both value and growth. Three recommended stocks for watchlists are TD SYNNEX (strong revenue growth and low valuation), Oscar Health (record results and significant earnings growth), and PBF Energy (strong cash flow and extremely low P/E ratio).

Zacks highlights three stocks with Rank #1 (Strong Buy) ratings and strong growth potential: Schneider National (SNDR), a logistics provider with 15.6% earnings estimate increase; National Energy Services Reunited (NESR), an oilfield services company with 8.3% earnings growth; and Oscar Health (OSCR), a healthcare technology company with a notable 227.7% earnings estimate increase over the last 60 days.

Oscar Health is positioned for significant market-beating returns through its technology-driven health insurance platform. The company is rapidly gaining market share in the ACA individual payor market (3.2 million members, up 50% YoY) and expanding into employer-funded individual contribution plans. With projected $19 billion in revenue by 2026 and potential to reach $50 billion, Oscar Health is entering a major profit inflection phase. The stock trades at a low valuation of 2.5x projected earnings at scale, offering substantial upside potential for long-term investors.

The article recommends three high-quality stocks suitable for 20-year holding periods: Nintendo, a durable gaming brand with strong hardware sales and high-margin game franchises; Oscar Health, a tech-enabled health insurance provider rapidly gaining market share; and Adyen, a payments processing company with superior execution and growing enterprise adoption. All three stocks are currently trading at significant discounts from their highs, presenting potential long-term value opportunities.

AMD surged approximately 20% following strong Q1 2026 earnings results, with the company stepping out of Nvidia's shadow. The article discusses whether the stock remains a buy or if investors should take profits, while also covering earnings reports from Oscar Health and Uber.

Health insurance stocks are currently beaten down due to political concerns and rising claims costs, but present long-term investment opportunities. UnitedHealth Group and Oscar Health are highlighted as undervalued plays poised for recovery as the sector rebounds in 2026, supported by structural growth in U.S. healthcare spending.

Contrarian investors identify three beaten-down sectors with buying opportunities: financials (American Express, KKR, Apollo Global Management, Blue Owl Capital, Robinhood), healthcare (Molina Healthcare, Oscar Health, Hims Hers Health), and software (Microsoft, Oracle, ServiceNow, Figma). They recommend avoiding energy stocks, which have rallied too far on momentum and FOMO despite potential long-term gains.

The Centers for Medicare & Medicaid Services announced a 2.48% increase in 2027 Medicare Advantage capitation rates, exceeding initial expectations of 0.09%. The boost amounts to over $13 billion in additional payments and reflects a 4.98% increase when accounting for risk score trends. CMS retained the 2024 risk adjustment model, providing greater rate predictability for insurers. Major healthcare stocks surged on the positive announcement.

Oscar Health, an ACA marketplace health insurer, has gained significant market share despite a 50% stock decline from October 2025 highs. The company added 1.4 million members to reach 3.4 million total, and expects to return to profitability with $250-450 million in operating income on $18.7-19 billion in revenue for 2026. Trading at less than 10x forward earnings, the stock appears undervalued despite headwinds from reduced government subsidies and higher healthcare costs.

Amid Nasdaq correction concerns driven by geopolitical tensions and oil price fears, the article recommends three stocks trading at attractive valuations: Oscar Health, a technology-forward health insurer gaining market share; Adyen, a dominant enterprise payment processor; and Remitly Global, a leader in digital money transfers. All three companies are positioned to thrive regardless of broader economic conditions.

Oscar Health stock rose nearly 2% on Tuesday despite missing analyst estimates on revenue ($2.8B vs. $3.1B expected) and posting a deeper net loss ($1.24 per share vs. $0.89 expected). The stock gained on bullish full-year 2026 guidance projecting $18.7-19B in revenue and $250-450M in operating earnings, along with strong membership growth exceeding 2 million members.

Oscar Health reported Q4 2025 revenue of $2.81B, missing estimates of $3.12B, with a loss of $1.24 per share. The company faced challenges from higher medical costs and morbidity in 2025 but projects a significant turnaround in 2026, guiding for $18.7-19B in revenue and $250-450M in operating earnings. Membership grew to 2.04M, and the company secured a $475M credit facility to strengthen its balance sheet.